PSTX240719P5000
- 2.10
- 0.000.00%
Poseida Therapeutics Newsroom
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
SAN DIEGO, July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
SAN DIEGO, June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Arthur He CFA maintains $Poseida Therapeutics(PSTX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 5
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Piper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
Poseida Therapeutics: A Strong Buy on Robust Pipeline, Strategic Partnerships, and Leadership Enhancements
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises
Poseida Therapeutics (PSTX) reported a Q1 loss late Tuesday of $0.25 per diluted share, narrowing from a loss of $0.45 a year earlier. Four of five analysts polled by Capital IQ expected a loss of $0.
Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate
Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. The company reported quarterly sales of $28.14
Poseida Therapeutics | 10-Q: Quarterly report
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M
04:12 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M
Press Release: Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire SAN DIEGO, May 14, 2024 Expanded strategic relationship with Astellas with new research collabo
Poseida Therapeutics 1Q Loss/Shr 25c >PSTX
Poseida Therapeutics 1Q Loss/Shr 25c >PSTX
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
Strong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing Capabilities
Strategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida Therapeutics
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
Poseida Therapeutics (PSTX) and Astellas Pharma subsidiary Xyphos Biosciences have entered into a research partnership and license agreement to develop new cancer cell therapy platforms using the Xyph
Biotech Soars on Research Collaboration And License Agreement Release